Vaxart, Inc. (VXRT)
OQX · Healthcare · Biotechnology
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About Vaxart, Inc.
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII; COVID-19 Vaccine, which is in Phase 2b clinical trial for the treatment of SARS-CoV-1, SARS-CoV-2, and Middle East respiratory syndrome coronavirus; Seasonal Influenza vaccine, which is in Phase 2 clinical trial, to treat H1N1 Influenza; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. The company also provides VAAST (Vector-Adjuvant-Antigen Standardized Technology) Platform, a unique modular vaccine platform. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 72.4M | 104.2M | 39.2M | 27.2M |
| Operating Income | (7.8M) | 55.4M | 5.2M | (13.2M) |
| Net Income | (8.1M) | 55.0M | 5.2M | (13.5M) |
| Diluted EPS | $-0.04 | N/A | $0.02 | $-0.06 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 107K | 7.4M | 28.7M | 237.3M |
| Operating Income | (110.3M) | (83.3M) | (66.3M) | 18.1M |
| Net Income | (107.8M) | (82.5M) | (66.9M) | 16.3M |
| Diluted EPS | $-0.84 | $-0.57 | $-0.33 | $0.07 |